Patents Assigned to Rhodes Technologies
-
Publication number: 20170022210Abstract: Processes for preparing oxycodone are provided. Said processes encompass a step which is a hydrogenation of an 14-hydroxycodeinone salt in the presence of trifluoroacetic acid and/or a glycol.Type: ApplicationFiled: January 15, 2015Publication date: January 26, 2017Applicant: RHODES TECHNOLOGIESInventors: Joshua Robert GIGUERE, Keith Edward MCCARTHY, Marcel SCHLEUSNER
-
Patent number: 9522919Abstract: In certain embodiments the invention is directed to a process for preparing an oxycodone hydrochloride composition having less than 25 ppm of 14-hydroxycodeinone.Type: GrantFiled: May 29, 2015Date of Patent: December 20, 2016Assignees: Purdue Pharma L.P., P.F. Laboratories, Inc., Purdue Pharmaceuticals L.P., Rhodes TechnologiesInventors: Robert Chapman, Lonn S. Rider, Qi Hong, Donald Kyle, Robert Kupper
-
Patent number: 9499557Abstract: The present disclosure provides processes for the N-dealkylation of tertiary amines and the use of transition metal catalysts to prepare tertiary N-allyl amine derivatives and secondary amine derivatives thereof. The tertiary amines can be alkaloids and, more particularly, the tertiary amines can be opioids. In specific embodiments, the present disclosure provides methods for use in processes for the synthesis of naloxone and naltrexone from oripavine.Type: GrantFiled: August 14, 2015Date of Patent: November 22, 2016Assignee: Rhodes TechnologiesInventors: Joshua Robert Giguere, Keith Edward McCarthy, Helge Alfred Reisch, Sergio Sandoval, Jake Larry Stymiest
-
Patent number: 9475770Abstract: The present invention describes a process for the preparation of methylphenidate hydrochloride. The process involves the esterification of ritalinic acid and methanol in the presence of an acid catalyst at a low temperature. The process may optionally involve the addition of an orthoester.Type: GrantFiled: December 16, 2011Date of Patent: October 25, 2016Assignee: Rhodes TechnologiesInventors: C. Frederick M. Huntley, Erik Wayne Kataisto, Knicholaus Dudley La Lumiere, Helge Alfred Reisch
-
Publication number: 20160264589Abstract: This invention relates to opioid ketal compounds of Formula (I), Formula (II), or Formula (III): or a pharmaceutically acceptable salts thereof, wherein R1 is H or CH3, R2 is H or OH, n is 0, 1, 2 or 3, R3 and R4 are independently H or optionally substituted C1-C4 alkyl, or when n is 0, then R3 and R4 and the carbon atoms to which they are attached together form six, or seven membered ring, which is optionally mono or disubstituted by C1-C4 alkyl. The invention also relates to oxycodone ketal compounds of Formula (IV) or (V): or a pharmaceutically acceptable salts thereof. The invention also relates to the use of such compounds for the treatment, prevention, or amelioration of pain.Type: ApplicationFiled: May 4, 2016Publication date: September 15, 2016Applicant: Rhodes TechnologiesInventors: Robert J. KUPPER, Raymond C. GLOWAKY
-
Publication number: 20160244459Abstract: This invention relates to opioid ketal compounds of Formula (I), Formula (II), or Formula (III): or a pharmaceutically acceptable salts thereof, wherein R1 is H or CH3, R2 is H or OH, n is 0, 1, 2 or 3, R3 and R4 are independently H or optionally substituted C1-C4 alkyl, or when n is 0, then R3 and R4 and the carbon atoms to which they are attached together form six, or seven membered ring, which is optionally mono or disubstituted by C1-C4 alkyl. The invention also relates to oxycodone ketal compounds of Formula (IV) or (V): or a pharmaceutically acceptable salts thereof. The invention also relates to the use of such compounds for the treatment, prevention, or amelioration of pain.Type: ApplicationFiled: May 23, 2014Publication date: August 25, 2016Applicant: RHODES TECHNOLOGIESInventors: Robert J. KUPPER, Raymond C. GLOWAKY
-
Patent number: 9315514Abstract: The application is directed to compounds of Formula I and pharmaceutically acceptable salts, prodrugs, and solvates thereof, wherein G, R2-R5, and are defined as set forth in the specification. The invention is also directed to use of compounds of Formula I as synthetic intermediates or to treat disorders responsive to the modulation of one or more opiopid receptors. Certain compounds of the present invention are especially useful for treating pain.Type: GrantFiled: August 26, 2013Date of Patent: April 19, 2016Assignee: Rhodes TechnologiesInventor: Helge A. Reisch
-
Patent number: 9309258Abstract: The present disclosure provides improved methods for N-dealkylation of tertiary amines, including methods for N-demethylation of alkaloids and opioids, in which the dealkylation reaction is carried out in a solvent comprising a tertiary alcohol. The present disclosure also provides improved processes for preparing semi-synthetic opioids that incorporate the disclosed methods for N-dealkylation of tertiary amines.Type: GrantFiled: December 2, 2014Date of Patent: April 12, 2016Assignee: Rhodes TechnologiesInventors: Joshua Robert Giguere, Helge Alfred Reisch, Sergio Sandoval, Jake Larry Stymiest
-
Patent number: 9127014Abstract: The present disclosure provides processes for the N-dealkylation of tertiary amines and the use of transition metal catalysts to prepare tertiary N-allyl amine derivatives and secondary amine derivatives thereof. The tertiary amines can be alkaloids and, more particularly, the tertiary amines can be opioids. In specific embodiments, the present disclosure provides methods for use in processes for the synthesis of naloxone and naltrexone from oripavine.Type: GrantFiled: December 11, 2012Date of Patent: September 8, 2015Assignee: Rhodes TechnologiesInventors: Joshua Robert Giguere, Keith Edward McCarthy, Helge Alfred Reisch, Sergio Sandoval, Jake Larry Stymiest
-
Patent number: 9073933Abstract: In certain embodiments the invention is directed to a process for preparing an oxycodone hydrochloride composition having less than 25 ppm of 14-hydroxycodeinone.Type: GrantFiled: February 6, 2012Date of Patent: July 7, 2015Assignees: Purdue Pharma L.P., The P.F. Laboratories, Inc., Purdue Pharmaceuticals L.P., Rhodes TechnologiesInventors: Robert Chapman, Lonn S. Rider, Qi Hong, Donald Kyle, Robert Kupper
-
Publication number: 20150038720Abstract: The present invention describes a process for the preparation of methylphenidate hydrochloride. The process involves the esterification of ritalinic acid and methanol in the presence of an acid catalyst at a low temperature. The process may optionally involve the addition of an orthoester.Type: ApplicationFiled: December 16, 2011Publication date: February 5, 2015Applicant: Rhodes TechnologiesInventors: C. Frederick M. Huntley, Erik Wayne Kataisto, Knicholaus Dudley La Lumiere, Helge Alfred Reisch
-
Patent number: 8921556Abstract: The present disclosure provides improved methods for N-dealkylation of tertiary amines, including methods for N-demethylation of alkaloids and opioids, in which the dealkylation reaction is carried out in a solvent comprising a tertiary alcohol. The present disclosure also provides improved processes for preparing semi-synthetic opioids that incorporate the disclosed methods for N-dealkylation of tertiary amines.Type: GrantFiled: December 11, 2012Date of Patent: December 30, 2014Assignee: Rhodes TechnologiesInventors: Joshua Robert Giguere, Helge Alfred Reisch, Sergio Sandoval, Jake Larry Stymiest
-
Patent number: 8822687Abstract: 8?,14-Dihydroxy-7,8-dihydrocodeinone is described.Type: GrantFiled: February 24, 2010Date of Patent: September 2, 2014Assignees: Purdue Pharma L.P., The P.F. Laboratories, Inc., Purdue Pharmaceuticals L.P., Rhodes TechnologiesInventors: Robert Chapman, Lonn S. Rider, Qi Hong, Donald Kyle, Robert Kupper
-
Publication number: 20140057932Abstract: The application is directed to compounds of Formula I and pharmaceutically acceptable salts, prodrugs, and solvates thereof, wherein G, R2-R5, and are defined as set forth in the specification. The invention is also directed to use of compounds of Formula I as synthetic intermediates or to treat disorders responsive to the modulation of one or more opiopid receptors. Certain compounds of the present invention are especially useful for treating pain.Type: ApplicationFiled: August 26, 2013Publication date: February 27, 2014Applicant: Rhodes TechnologiesInventor: Helge A. REISCH
-
Publication number: 20130102780Abstract: The present disclosure provides processes for the N-dealkylation of tertiary amines and the use of transition metal catalysts to prepare tertiary N-allyl amine derivatives and secondary amine derivatives thereof. The tertiary amines can be alkaloids and, more particularly, the tertiary amines can be opioids. In specific embodiments, the present disclosure provides methods for use in processes for the synthesis of naloxone and naltrexone from oripavine.Type: ApplicationFiled: December 11, 2012Publication date: April 25, 2013Applicant: Rhodes TechnologiesInventor: Rhodes Technologies
-
Publication number: 20130102784Abstract: The present disclosure provides improved methods for N-dealkylation of tertiary amines, including methods for N-demethylation of alkaloids and opioids, in which the dealkylation reaction is carried out in a solvent comprising a tertiary alcohol. The present disclosure also provides improved processes for preparing semi-synthetic opioids that incorporate the disclosed methods for N-dealkylation of tertiary amines.Type: ApplicationFiled: December 11, 2012Publication date: April 25, 2013Applicant: Rhodes TechnologiesInventor: Rhodes Technologies
-
Publication number: 20130005977Abstract: In certain embodiments the invention is directed to a process for preparing an oxycodone hydrochloride composition having less than 25 ppm of 14-hydroxycodeinone.Type: ApplicationFiled: February 6, 2012Publication date: January 3, 2013Applicants: Purdue Pharma L.P., Rhodes Technologies, Purdue Pharmaceuticals L.P., The P.F. Laboratories, Inc.Inventors: Robert Chapman, Lonn S. Rider, Qi Hong, Donald Kyle, Robert Kupper
-
Patent number: 8163731Abstract: A method of reducing the concentration of a chemical or drug substance in the blood plasma that targets the same or similar receptors as the normal neurotransmitters in the central or peripheral nervous system includes titrating an initial peak concentration of the chemical or drug substance in the blood for a predefined dosing period, titrating a lowest concentration level of the chemical or drug substance in the blood immediately before the end of the dosing period, and providing a plurality of subsequent dosing periods where each subsequent dosing period requires administration of a dosing amount of the chemical or drug substance and titrating of the peak concentration and the lowest concentration level to ensure that the lowest concentration level of the chemical or drug substance in the blood plasma for the subsequent dosing period is decreased by not more than five percent of the lowest concentration level of the previous dosing period and where the plurality of dosing periods added together extends theType: GrantFiled: August 20, 2008Date of Patent: April 24, 2012Assignee: Rhodes TechnologiesInventors: Kenneth C. Slater, Brenda E. Richardson, Scott M. Connors, Wei-wei Chang
-
Patent number: 5384121Abstract: The present invention relates to a method for the extraction of sesquiterpene lactones from the plant Tanacetum parthenium specifically using polar organic solvents and the use of such extracts in pharmaceutical products. It has been found that by utilization of an extraction procedure in accordance with the current invention, a significantly greater amount of the sesquiterpene lactone parthenolide is extracted from Tanacetum parthenium than is the case when using petroleum spirit as the primary extractant, the solvent usually used in previous studies.Type: GrantFiled: July 8, 1993Date of Patent: January 24, 1995Assignee: Rhodes TechnologyInventor: Alan Rhodes